Clinical Trials Browser

Lymphoma, T-Cell × duvelisib × 90 days × Clear all

NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2 Suspended

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT07293403 2026-06-02

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Phase 2 Recruiting

Lymphoma, T-Cell

NCT04331119 2026-05-06

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Phase 2 Terminated

Lymphoma, T-Cell

NCT02783625 2026-04-24

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Phase 1 Completed

Lymphoma, Lymphoma, T-Cell

NCT05010005 2026-04-09

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic